0001104659-23-071762.txt : 20230615
0001104659-23-071762.hdr.sgml : 20230615
20230615200507
ACCESSION NUMBER: 0001104659-23-071762
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230613
FILED AS OF DATE: 20230615
DATE AS OF CHANGE: 20230615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Potts Jeannette
CENTRAL INDEX KEY: 0001814693
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36294
FILM NUMBER: 231019089
MAIL ADDRESS:
STREET 1: C/O FORMA THERAPEUTICS HOLDINGS, INC.
STREET 2: 500 ARSENAL STREET, SUITE 100
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: uniQure N.V.
CENTRAL INDEX KEY: 0001590560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
BUSINESS PHONE: 1-339-970-7000
MAIL ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
FORMER COMPANY:
FORMER CONFORMED NAME: uniQure B.V.
DATE OF NAME CHANGE: 20131030
4
1
tm2318865-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-13
0
0001590560
uniQure N.V.
QURE
0001814693
Potts Jeannette
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
AMSTERDAM
P7
1105BP
NETHERLANDS
0
1
0
0
See Remarks
0
Ordinary Shares
2023-06-13
4
A
0
47100
0.0
A
47100
D
Option (Right to Buy)
20.18
2023-06-13
4
A
0
81300
0
A
2033-06-13
Ordinary Shares
81300
81300
D
The Reporting Person was granted 47,100 restricted share units in connection with the Reporting Person's appointment as Chief Legal and Compliance Officer of the Issuer. The restricted share units were granted as an inducement grant pursuant to Nasdaq listing rule 5635(c)(4). Each restricted share unit represents the contingent right to receive one ordinary share of the Issuer. The restricted share units vest in three approximately equal annual installments, with the first vesting date to occur on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
The option vests over four years, with 25% of the shares underlying such option vesting on the first anniversary of the date of grant and 6.25% of the shares underlying such option vesting quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
Chief Legal and Compliance Officer
/s/ Christian Klemt, Attorney-in-Fact
2023-06-15